Armistice Capital’s Autolus Therapeutics AUTL Stock Holding History

Armistice Capital’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24M	Sell	15,000,000 -800,000	-5%	-$1.26M	0.29%	54
2026 Q1	$21.8M	Sell	15,800,000 -1,700,000	-10%	-$2.58M	0.39%	52
2025 Q4	$34.8M	Buy	17,500,000 +1,900,000	+12%	+$2.92M	0.41%	41
2025 Q3	$25.4M	Buy	15,600,000 +3,600,000	+30%	+$7.03M	0.38%	41
2025 Q2	$27.4M	Buy	12,000,000 +1,000,000	+9%	+$1.65M	0.47%	32
2025 Q1	$17.1M	Buy	11,000,000 +1,800,000	+20%	+$3.65M	0.26%	74
2024 Q4	$21.6M	Buy	9,200,000 +2,328,000	+34%	+$7.87M	0.3%	67
2024 Q3	$24.9M	Buy	6,872,000 +622,000	+10%	+$2.48M	0.4%	45
2024 Q2	$21.8M	Buy	6,250,000 +1,578,000	+34%	+$6.81M	0.27%	62
2024 Q1	$29.8M	Buy	4,672,000 +822,000	+21%	+$5.13M	0.4%	40
2023 Q4	$24.8M	Sell	3,850,000 -3,050,000	-44%	-$11.6M	0.34%	53
2023 Q3	$16.1M	Sell	6,900,000 -364,000	-5%	-$1.04M	0.25%	65
2023 Q2	$17.3M	Sell	7,264,000 -2,408,000	-25%	-$5.71M	0.25%	75
2023 Q1	$17.8M	Sell	9,672,000 -552,000	-5%	-$1.08M	0.26%	70
2022 Q4	$19.4M	Buy	+10,224,000	New	+$25.9M	0.34%	57

Other funds holding AUTL

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Armistice Capital's AUTL Position: Q2 2026 in Review

Armistice Capital reduced its Autolus Therapeutics (AUTL) stake by 5.1% in Q2 2026, selling an estimated $1.26M and leaving 15,000,000 shares worth $24M. The position accounts for 0.29% of the portfolio, ranked #54.

Armistice Capital first reported a position in AUTL in Q4 2022 and has held it in 15 quarters since. The position peaked at $34.8M in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

Armistice Capital held 15,000,000 shares of Autolus Therapeutics worth $24M as of Q2 2026.
Armistice Capital sold 800,000 Autolus Therapeutics shares in Q2 2026, an estimated $1.26M.
Autolus Therapeutics made up 0.29% of Armistice Capital's portfolio in Q2 2026, its #54 holding.
Armistice Capital first reported a position in Autolus Therapeutics in Q4 2022 and has held it in 15 quarters since.
Armistice Capital's Autolus Therapeutics position peaked at $34.8M in Q4 2025.
84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.